[Construction and application of a recombinant plasmid inducing cell death in hepatocytes after transfection]

Area of Science:

• Cell Biology
• Regenerative Medicine
• Molecular Biology

Background:

• Mesenchymal stromal cells (MSCs) show therapeutic potential for liver damage.
• The exact mechanisms of MSCs in treating liver injury, including paracrine effects and direct trans-differentiation, remain unclear.
• Distinguishing between these mechanisms is crucial for optimizing MSC-based therapies.

Purpose of the Study:

• To construct a novel recombinant plasmid to investigate the mechanisms of MSCs in liver damage treatment.
• To create a tool that links MSC differentiation into hepatocytes with a cell death pathway.
• To differentiate between paracrine signaling and direct cell trans-differentiation as the primary mechanism of MSCs in liver repair.

Main Methods:

• Construction of a recombinant eukaryotic expression vector, pFlag-CMV-GFP-TM-albp-PE40.
• Utilized Polymerase Chain Reaction (PCR) to obtain green fluorescent protein (GFP), transmembrane domain of DLL1, albumin (alb) promoter, and Pseudomonas aeruginosa exotoxin 40 (PE40).
• Verified GFP expression via fluorescence microscopy and assessed hepatocyte cell death using flow cytometry.

Main Results:

• Successfully constructed the recombinant plasmid designed to induce cell death in hepatocytes upon MSC differentiation.
• The developed plasmid system allows for the visualization of GFP expression and quantification of cell death.
• Demonstrated the feasibility of using this construct to study MSC-mediated liver damage mechanisms.

Conclusions:

• The study successfully engineered a recombinant plasmid as a tool to investigate MSC mechanisms in liver disease.
• This tool provides a promising approach to elucidate whether MSCs exert their therapeutic effects through direct trans-differentiation or other pathways.
• Further research using this construct can advance the understanding and application of MSC-based therapies for liver diseases.